RxDoctor Payments Data

Samih Abbassi, MD

Internal Medicine · West Orange, NJNPI 1750380358

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 37 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medicure Pharma Inc.$303
  • GSK$129
  • Astellas Pharma US Inc$126
  • Qiagen, LLC$119
  • Gilead$104
  • Amarin Pharma, Inc.$94
  • plus $273 from 10 others

What the payments were for

  • Food & beverage$1,04891%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,147 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$25,065
Medicare patients
99
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin147$140,595
OzempicSemaglutide50$62,221
Dupixent SyringeDupilumab13$54,488
FarxigaDapagliflozin Propanediol56$42,246
EliquisApixaban45$39,283
EntrestoSacubitril/Valsartan29$27,697
JanumetSitagliptin Phos/Metformin Hcl27$27,152
Bydureon BciseExenatide Microspheres32$25,462
TrulicityDulaglutide16$22,586
JanuviaSitagliptin Phosphate18$19,940
XareltoRivaroxaban11$14,793
MyrbetriqMirabegron29$14,184
TradjentaLinagliptin17$13,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,618
Atorvastatin Calcium425$4,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$57$153,660164 claims
Novo NordiskOzempic$43$62,22150 claims
PfizerEliquis$12$39,28345 claims
NovartisEntresto$28$27,69729 claims
Lilly USA, LLCTrulicity$23$22,58616 claims
Astellas Pharma US IncMyrbetriq$126$14,18429 claims
GSKTrelegy Ellipta$129$12,61819 claims
Sanofi-aventis U.S. LLCLantus$29$84713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →